{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T19:01:20Z","timestamp":1789758080399,"version":"4.0.1"},"reference-count":60,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1002\/jps.24489","type":"journal-article","created":{"date-parts":[[2015,5,15]],"date-time":"2015-05-15T18:27:14Z","timestamp":1431714434000},"page":"3220-3228","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":66,"title":["The Use of Transporter Probe Drug Cocktails for the Assessment of Transporter-Based Drug\u2013Drug Interactions in a Clinical Setting\u2014Proposal of a Four Component Transporter Cocktail"],"prefix":"10.1016","volume":"104","author":[{"given":"Thomas","family":"Ebner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Ishiguro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell E.","family":"Taub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1002\/jps.24489_bb0005","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/clpt.2013.45","article-title":"ITC recommendations for transporter kinetic parameter estimation and translational modeling of transport-mediated PK and DDIs in humans","volume":"94","author":"Zamek-Gliszczynski","year":"2013","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1002\/jps.24489_bb0010","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrd3028","article-title":"Membrane transporters in drug development","volume":"9","author":"Giacomini","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.1002\/jps.24489_bb0015","series-title":"FDA drug interaction studies\u2014Study design, data analysis, implications for dosing, and labeling recommendations","author":"Food","year":"2012"},{"key":"10.1002\/jps.24489_bb0020","author":"European Medicines Agency","year":"2012"},{"key":"10.1002\/jps.24489_bb0025","author":"Ministry of Health, Labor and Welfare","year":"2014"},{"issue":"1","key":"10.1002\/jps.24489_bb0030","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.pharmthera.2009.03.017","article-title":"Drug interactions at the blood\u2013brain barrier: Fact or fantasy?","volume":"123","author":"Eyal","year":"2009","journal-title":"Pharmacol Ther"},{"issue":"7","key":"10.1002\/jps.24489_bb0035","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1124\/dmd.112.050500","article-title":"Variability in P-glycoprotein inhibitory potency (IC50) using various in vitro experimental systems: Implications for universal digoxin drug\u2013drug interaction risk assessment decision criteria","volume":"41","author":"Bentz","year":"2013","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"10.1002\/jps.24489_bb0040","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1067\/mcp.2000.109519","article-title":"Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the \u2018Cooperstown cocktail\u2019","volume":"68","author":"Streetman","year":"2000","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"10.1002\/jps.24489_bb0045","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0009-9236(97)90114-4","article-title":"Validation of the five-drug \u2018Pittsburgh cocktail\u2019 approach for assessment of selective regulation of drug-metabolizing enzymes","volume":"62","author":"Frye","year":"1997","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"10.1002\/jps.24489_bb0050","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/clpt.2010.158","article-title":"An evaluation of the drug interaction potential of pazopanib, an oral vascular endothelial growth factor receptor tyrosine kinase inhibitor, using a modified cooperstown 51 cocktail in patients with advanced solid tumors","volume":"88","author":"Goh","year":"2010","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1002\/jps.24489_bb0055","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1124\/dmd.112.048470","article-title":"Evaluation and prediction of potential drug\u2013drug interactions of linagliptin using in vitro cell culture methods","volume":"41","author":"Ishiguro","year":"2013","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1002\/jps.24489_bb0060","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1124\/jpet.104.068056","article-title":"Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans","volume":"311","author":"Hirano","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"issue":"10","key":"10.1002\/jps.24489_bb0065","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1124\/dmd.114.058545","article-title":"Brain penetration of WEB 2086 (Apafant) and dantrolene in Mdr1a (P-gp) and Bcrp knockout rats","volume":"42","author":"Fuchs","year":"2014","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"10.1002\/jps.24489_bb0070","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1124\/dmd.113.053769","article-title":"In vitro predictability of drug\u2013drug interaction likelihood of P-glycoprotein-mediated efflux of dabigatran etexilate based on [I]2\/IC50 threshold","volume":"42","author":"Kishimoto","year":"2014","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"10.1002\/jps.24489_bb0075","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3109\/00498250903509375","article-title":"Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1","volume":"40","author":"Annaert","year":"2010","journal-title":"Xenobiotica"},{"issue":"11","key":"10.1002\/jps.24489_bb0080","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1124\/dmd.111.040816","article-title":"Digoxin is not a substrate for organic anion-transporting polypeptide transporters OATP1A2, OATP1B1, OATP1B3, and OATP2B1 but is a substrate for a sodium-dependent transporter expressed in HEK293 cells","volume":"39","author":"Taub","year":"2011","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1002\/jps.24489_bb0085","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ejpb.2005.06.001","article-title":"Development of a fluorescence-based assay for screening of modulators of human organic anion transporter 1B3 (OATP1B3)","volume":"62","author":"Baldes","year":"2006","journal-title":"Eur J Pharm Biopharm"},{"issue":"5","key":"10.1002\/jps.24489_bb0090","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1002\/jps.23491","article-title":"Chlorothiazide is a substrate for the human uptake transporters OAT1 and OAT3","volume":"102","author":"Juhasz","year":"2013","journal-title":"J Pharm Sci"},{"issue":"4","key":"10.1002\/jps.24489_bb0095","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1124\/dmd.32.4.424","article-title":"Expression studies and functional characterization of renal human organic anion transporter 1 isoforms","volume":"32","author":"Bahn","year":"2004","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"10.1002\/jps.24489_bb0100","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1124\/jpet.106.116517","article-title":"Transport of the dipeptidyl peptidase-4 inhibitor sitagliptin by human organic anion transporter 3, organic anion transporting polypeptide 4C1, and multidrug resistance P-glycoprotein","volume":"321","author":"Chu","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"10.1002\/jps.24489_bb0105","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1124\/jpet.107.125831","article-title":"The contribution of organic anion transporters OAT1 and OAT3 to the renal uptake of rosuvastatin","volume":"322","author":"Windass","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"10.1002\/jps.24489_bb0110","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1124\/dmd.113.054767","article-title":"Interaction of novel platelet-increasing agent eltrombopag with rosuvastatin via breast cancer resistance protein in humans","volume":"42","author":"Takeuchi","year":"2014","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"10.1002\/jps.24489_bb0115","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1124\/mol.112.084152","article-title":"Structure-based identification of OATP1B1\/3 inhibitors","volume":"83","author":"Bruyn","year":"2013","journal-title":"Mol Pharmacol"},{"issue":"6","key":"10.1002\/jps.24489_bb0120","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1080\/00498250701397705","article-title":"Comparison of the kinetic characteristics of inhibitory effects exerted by biguanides and H2-blockers on human and rat organic cation transporter-mediated transport: Insight into the development of drug candidates","volume":"37","author":"Umehara","year":"2007","journal-title":"Xenobiotica"},{"issue":"8","key":"10.1002\/jps.24489_bb0125","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1023\/A:1019870831174","article-title":"Interactions of n-tetraalkylammonium compounds and biguanides with a human renal organic cation transporter (hOCT2)","volume":"19","author":"Dresser","year":"2002","journal-title":"Pharm Res"},{"issue":"1","key":"10.1002\/jps.24489_bb0130","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1124\/jpet.108.147918","article-title":"Involvement of human multidrug and toxin extrusion 1 in the drug interaction between cimetidine and metformin in renal epithelial cells","volume":"329","author":"Tsuda","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1002\/jps.24489_bb0135","series-title":"LANOXIN\u00ae, drug label","author":"Covis Pharma","year":"2011"},{"issue":"6","key":"10.1002\/jps.24489_bb0140","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1111\/j.1365-2125.2007.03035.x","article-title":"Sublingual administration of furosemide: New application of an old drug","volume":"64","author":"Haegeli","year":"2007","journal-title":"Br J Clin Pharmacol"},{"key":"10.1002\/jps.24489_bb0145","series-title":"Goodman & Gilman\u2019s the pharmacological basis of therapeutics","author":"Brunton","year":"2011"},{"issue":"2","key":"10.1002\/jps.24489_bb0150","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.clpt.2004.03.010","article-title":"Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine","volume":"76","author":"Simonson","year":"2004","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"10.1002\/jps.24489_bb0155","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1111\/bcp.12079","article-title":"Trimethoprim-metformin interaction and its genetic modulation by OCT2 and MATE1 transporters","volume":"76","author":"Gr\u00fcn","year":"2013","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"10.1002\/jps.24489_bb0160","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1038\/clpt.2011.351","article-title":"Transporter-mediated drug\u2013drug interactions involving OATP substrates: Predictions based on in vitro inhibition studies","volume":"91","author":"Yoshida","year":"2012","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1002\/jps.24489_bb0165","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s40262-013-0097-y","article-title":"A mechanistic framework for in vitro\u2013in vivo extrapolation of liver membrane transporters: Prediction of drug\u2013drug interaction between rosuvastatin and cyclosporine","volume":"53","author":"Jamei","year":"2014","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"10.1002\/jps.24489_bb0170","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1124\/dmd.111.038075","article-title":"Use of transporter knockdown Caco-2 cells to investigate the in vitro efflux of statin drugs","volume":"39","author":"Li","year":"2011","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"10.1002\/jps.24489_bb0175","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1002\/jps.23069","article-title":"Differential selectivity of efflux transporter inhibitors in Caco-2 and MDCK-MDR1 monolayers: A strategy to assess the interaction of a new chemical entity with P-gp, BCRP, and MRP2","volume":"101","author":"Mease","year":"2012","journal-title":"J Pharm Sci"},{"key":"10.1002\/jps.24489_bb0180","series-title":"CRESTOR\u00ae, drug label","author":"AstraZeneca","year":"2013"},{"key":"10.1002\/jps.24489_bb0185","series-title":"LASIX\u00ae, drug label","author":"Sanofi-Aventis","year":"2011"},{"key":"10.1002\/jps.24489_bb0190","series-title":"GLUCOPHAGE\u00ae, drug label","author":"Squibb","year":"2008"},{"issue":"4","key":"10.1002\/jps.24489_bb0195","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1208\/s12248-011-9290-9","article-title":"BDDCS applied to over 900 drugs","volume":"13","author":"Benet","year":"2011","journal-title":"AAPS J"},{"issue":"21","key":"10.1002\/jps.24489_bb0200","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1007\/BF01476555","article-title":"The pharmacokinetics of digoxin during chronic spironolacton treatment","volume":"56","author":"Masson","year":"1978","journal-title":"Klin Wochenschr"},{"issue":"1","key":"10.1002\/jps.24489_bb0205","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/BF00613429","article-title":"On the fate of furosemide in man","volume":"9","author":"Beermann","year":"1975","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1002\/jps.24489_bb0210","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/BF00562061","article-title":"Pharmacokinetics of metformin after intravenous and oral administration to man","volume":"16","author":"Pentikainen","year":"1979","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"10.1002\/jps.24489_bb0215","first-page":"39","article-title":"Pharmacokinetic studies of nifedipine and digoxin co-administration","volume":"24","author":"Koren","year":"1986","journal-title":"Int J Clin Pharmacol Ther Toxicol"},{"issue":"10","key":"10.1002\/jps.24489_bb0220","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1016\/S0149-2918(03)80316-8","article-title":"Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers","volume":"25","author":"Martin","year":"2003","journal-title":"Clin Ther"},{"issue":"6","key":"10.1002\/jps.24489_bb0225","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1038\/clpt.1980.111","article-title":"Renal tubular secretion and effects of furosemide","volume":"27","author":"Odlind","year":"1980","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1002\/jps.24489_bb0230","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1053\/gast.2001.21176","article-title":"Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver","volume":"120","author":"Kullak-Ublick","year":"2001","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1002\/jps.24489_bb0235","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/clpt.2010.271","article-title":"Rifampin\u2019s acute inhibitory and chronic inductive drug interactions: Experimental and model-based approaches to drug-drug interaction trial design","volume":"89","author":"Reitman","year":"2011","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1002\/jps.24489_bb0240","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1002\/jps.23851","article-title":"In vitro\u2013in vivo extrapolation method to predict human renal clearance of drugs","volume":"103","author":"Kunze","year":"2014","journal-title":"J Pharm Sci"},{"issue":"9","key":"10.1002\/jps.24489_bb0245","doi-asserted-by":"crossref","first-page":"3436","DOI":"10.1002\/jps.23523","article-title":"Kinetic analysis of human and canine P-glycoprotein-mediated drug transport in MDR1-MDCK cell model: Approaches to reduce false-negative substrate classification","volume":"102","author":"Li","year":"2013","journal-title":"J Pharm Sci"},{"issue":"10","key":"10.1002\/jps.24489_bb0250","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1124\/dmd.108.021410","article-title":"Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin","volume":"36","author":"Kitamura","year":"2008","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"10.1002\/jps.24489_bb0255","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1124\/dmd.110.034629","article-title":"Attenuation of intestinal absorption by major efflux transporters: Quantitative tools and strategies using a Caco-2 model","volume":"39","author":"Lin","year":"2011","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"10.1002\/jps.24489_bb0260","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1124\/jpet.103.059139","article-title":"Interactions of human organic anion transporters with diuretics","volume":"308","author":"Hasannejad","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1002\/jps.24489_bb0265","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/978-3-642-14541-4_3","article-title":"Organic cation transporters (OCTs, MATEs), in vitro and in vivo evidence for the importance in drug therapy","volume":"201","author":"Nies","year":"2011","journal-title":"Handb Exp Pharmacol"},{"issue":"4","key":"10.1002\/jps.24489_bb0270","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.ajog.2010.01.035","article-title":"Role of human placental apical membrane transporters in the efflux of glyburide, rosiglitazone, and metformin","volume":"202","author":"Hemauer","year":"2010","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"10.1002\/jps.24489_bb0275","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jcph.200","article-title":"Suitability of digoxin as a P-glycoprotein probe: Implications of other transporters on sensitivity and specificity","volume":"54","author":"Nader","year":"2014","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"10.1002\/jps.24489_bb0280","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s00228-013-1592-7","article-title":"Effects of vercirnon on the activity of CYP3A4, CYP2C19 and CYP2C8 enzymes and BCRP and OATP1B1 transporters using probe substrates","volume":"70","author":"Haberer","year":"2014","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"10.1002\/jps.24489_bb0285","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/bcp.12377","article-title":"Pitavastatin is a more sensitive and selective organic anion-transporting polypeptide 1B clinical probe than rosuvastatin","volume":"78","author":"Prueksaritanont","year":"2014","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"10.1002\/jps.24489_bb0290","doi-asserted-by":"crossref","first-page":"F997","DOI":"10.1152\/ajprenal.00431.2009","article-title":"Human multidrug and toxin extrusion 1 (MATE1\/SLC47A1) transporter: functional characterization, interaction with OCT2 (SLC22A2), and single nucleotide polymorphisms","volume":"298","author":"Meyer zu Schwabedissen","year":"2010","journal-title":"Am J Physiol Renal Physiol"},{"issue":"1","key":"10.1002\/jps.24489_bb0295","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1124\/dmd.111.042259","article-title":"Simultaneous absolute protein quantification of transporters, cytochromes P450, and UDP-glucuronosyltransferases as a novel approach for the characterization of individual human liver: Comparison with mRNA levels and activities","volume":"40","author":"Ohtsuki","year":"2012","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1002\/jps.24489_bb0300","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1681\/ASN.2005090966","article-title":"Multidrug resistance-associated protein 4 is involved in the urinary excretion of hydrochlorothiazide and furosemide","volume":"18","author":"Hasegawa","year":"2007","journal-title":"J Am Soc Nephrol"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354916301022?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354916301022?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T09:27:26Z","timestamp":1758360446000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354916301022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":60,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["S0022354916301022"],"URL":"https:\/\/doi.org\/10.1002\/jps.24489","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Use of Transporter Probe Drug Cocktails for the Assessment of Transporter-Based Drug\u2013Drug Interactions in a Clinical Setting\u2014Proposal of a Four Component Transporter Cocktail","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1002\/jps.24489","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Wiley Periodicals, Inc. and the American Pharmacists Association. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}